TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

Mr. Hutchison’s change came in the wake of Tuesday’s premarket release of fourth-quarter 2024 operating results and updated ...

Investors have found chocolate stocks to be an appealing investment since they have experienced financial gains. As of ...

The EU will respond in a "firm and proportionate way" to a decision by US President Donald Trump to impose tariffs on the ...

On Tuesday, during a House Financial Services Committee hearing, U.S. lawmakers exhibited a divide in their approaches to regulating cryptocurrencies and stablecoins, highlighting the challenges in ...

Trumpian policy is about elevating cultural policy above all else. He doesn’t have to win the cultural debates, but he will control the ideological agenda.

TD Cowen reiterated its Buy rating on Apollo Global Management (NYSE:APO) shares, maintaining a price target of $214.00.

Ryan Konik, Co-Founder and Partner at Titan, added, "Dr. Peaker's technical background, combined with his sell-side research experience, makes him an exceptional fit for our platform. His addition ...

Darts legend Phil Taylor has predicted a humongous increase in prize money – and it could tempt him to brush off the darts. Last week, Barry Hearn exclusively told talkSPORT that there is ...